Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07826689) titled 'A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis' on Sept. 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Progentos Therapeutics

Condition: Multiple Sclerosis

Intervention: Drug: PRO-1562 Oral Capsules

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: October 2026

Target Sample Size: 160

Countries of Recruitment: Australia

T...